![MoonLake Immunotherapeutics](/common/images/company/N_MLTX.png)
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases. MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.
MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11 Initiated Phase 3 VELA program of the Nanobody® sonelokimab in...
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis Builds upon the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 3.93 | 8.8813559322 | 44.25 | 48.57 | 43.535 | 236830 | 46.96317022 | CS |
4 | 3.23 | 7.18576195773 | 44.95 | 48.57 | 39.36 | 337047 | 44.1192225 | CS |
12 | 7.04 | 17.1122994652 | 41.14 | 50.53 | 37.55 | 356423 | 43.30022231 | CS |
26 | -10.91 | -18.4633609748 | 59.09 | 59.735 | 37.55 | 406458 | 45.42798468 | CS |
52 | -9.83 | -16.9453542493 | 58.01 | 64.98 | 35.11 | 498121 | 49.30378863 | CS |
156 | 35.81 | 289.490703314 | 12.37 | 64.98 | 4.25 | 355198 | 42.11167827 | CS |
260 | 35.81 | 289.490703314 | 12.37 | 64.98 | 4.25 | 355198 | 42.11167827 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.